We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Fed. Circ. Backs Decision Axing 4 Acorda MS Drug Patents

Law360 (September 10, 2018, 9:01 PM EDT) -- A split Federal Circuit panel on Monday upheld a judge’s decision that four patents on Acorda Therapeutics Inc.’s multiple sclerosis drug Ampyra are invalid as obvious, clearing the way for competing...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.